Weekly Investment Analysts’ Ratings Changes for ProQR Therapeutics (PRQR)

Several analysts have recently updated their ratings and price targets for ProQR Therapeutics (NASDAQ: PRQR):

• 8/20/2026 – ProQR Therapeutics is now covered by Bank of America Corporation. They set a “buy” rating and a $8.00 price target on the stock.
• 8/17/2026 – ProQR Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 8/15/2026 – ProQR Therapeutics was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 8/14/2026 – ProQR Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insider Activity

In other news, Director Bart Filius acquired 150,000 shares of ProQR Therapeutics stock in a transaction that occurred on Friday, July 17th. The shares were bought at an average cost of $1.72 per share, with a total value of $258,000.00. Following the transaction, the director directly owned 300,000 shares of the company’s stock, valued at $516,000. This trade represents a 100.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO Boer Daniel Anton De bought 150,000 shares of the company’s stock in a transaction on Thursday, July 9th. The shares were acquired at an average price of $1.74 per share, with a total value of $261,000.00. Following the transaction, the chief executive officer directly owned 300,000 shares of the company’s stock, valued at approximately $522,000. This trade represents a 100.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 600,000 shares of company stock worth $988,500 over the last quarter. 8.40% of the stock is currently owned by insiders.

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.